➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AIN457

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AIN457?

AIN457 is an investigational drug.

There have been 52 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.

The most common disease conditions in clinical trials are Arthritis, Psoriasis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Yanqiao Zhang, and Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

There are three US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for AIN457
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC(SHR-1210-AIN457)Yanqiao ZhangPhase 1/Phase 2
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisNovartis PharmaceuticalsPhase 3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis SuppurativaNovartis PharmaceuticalsPhase 3

See all AIN457 clinical trials

Clinical Trial Summary for AIN457

Top disease conditions for AIN457
Top clinical trial sponsors for AIN457

See all AIN457 clinical trials

US Patents for AIN457

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AIN457   Start Trial Methods of administering IgG1 antibodies and methods of suppressing angiogenesis University of Kentucky Research Foundation (Lexington, KY)   Start Trial
AIN457   Start Trial Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)   Start Trial
AIN457   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AIN457

Drugname Country Document Number Estimated Expiration Related US Patent
AIN457 Canada 2907548 2033-03-13   Start Trial
AIN457 European Patent Office 2968556 2033-03-13   Start Trial
AIN457 World Intellectual Property Organization (WIPO) 2014160336 2033-03-13   Start Trial
AIN457 World Intellectual Property Organization (WIPO) 2013086208 2031-12-06   Start Trial
AIN457 European Patent Office 2796429 2033-04-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.